Advanced Enzyme Technologies Limited – Investor Presentation Summary

Key Operational Highlights

  • Human Nutrition segment contributed 60% of total revenue in Q2 FY27
  • Animal Nutrition segment contributed 12% of total revenue in Q2 FY27
  • Industrial Bio-Processing segment contributed 17% of total revenue in Q2 FY27
  • Specialized Manufacturing segment contributed 11% of total revenue in Q2 FY27

Segment-wise Performance

Human Nutrition:

  • Q2 FY27: ₹1,285 million (6% YoY growth from ₹1,212 million in Q2 FY26, 11% QoQ growth)
  • H1 FY27: ₹2,443 million (flat YoY from ₹2,434 million in H1 FY26)
  • Contributed 60% to total revenue in both Q2 and H1 FY27

Animal Nutrition:

  • Q2 FY27: ₹265 million (37% YoY growth from ₹193 million in Q2 FY26, 5% QoQ growth)
  • H1 FY27: ₹517 million (14% YTD growth from ₹452 million in H1 FY26)
  • Contributed 12% to total revenue in Q2 FY27 and 13% in H1 FY27

Industrial Bio-Processing:

  • Q2 FY27: ₹365 million (43% YoY growth from ₹255 million in Q2 FY26, 19% QoQ growth)
  • H1 FY27: ₹671 million (37% YTD growth from ₹491 million in H1 FY26)
  • Food business within segment: Q2 FY27 ₹305 million (48% YoY growth, 16% QoQ growth)
  • Non-Food business within segment: Q2 FY27 ₹60 million (21% YoY growth, 37% QoQ growth)
  • Food business contributed 14% to overall revenue in H1 FY27 at ₹568 million
  • Non-Food business contributed 3% to overall revenue in H1 FY27 at ₹103 million

Specialized Manufacturing:

  • Q2 FY27: ₹231 million (25% YoY growth, 15% QoQ growth)
  • H1 FY27: ₹431 million (32% YTD growth from ₹327 million in H1 FY26)
  • Contributed 11% to total revenue in Q2 and H1 FY27

Financial Highlights

Q2 FY27 Performance:

  • Revenue: ₹2,145 million (16% YoY growth from ₹1,845 million, 12% QoQ growth from ₹1,917 million)
  • EBITDA: ₹721 million (20% YoY growth from ₹601 million, 36% QoQ growth from ₹529 million)
  • PAT: ₹512 million (14% YoY growth from ₹447 million, 33% QoQ growth from ₹386 million)
  • EPS: ₹4.33 (12% YoY growth from ₹3.87, 30% QoQ growth from ₹3.31)
  • EBITDA Margin: 34%
  • PAT Margin: 24%

H1 FY27 Performance:

  • Revenue: ₹4,062 million (10% YTD growth from ₹3,704 million)
  • EBITDA: ₹1,250 million (7% YTD growth from ₹1,165 million)
  • PAT: ₹897 million (5% YTD growth from ₹852 million)
  • EPS: ₹7.64 (3% YTD growth from ₹7.44)
  • EBITDA Margin: 31%
  • PAT Margin: 22%

Profit & Loss Details (Consolidated):

  • Expenses: Q2 FY27 ₹1,533 million (14% YoY growth, 3% QoQ growth)
  • Profit from Operations before Other Income: Q2 FY27 ₹612 million (22% YoY growth, 42% QoQ growth)
  • Other Income: Q2 FY27 ₹87 million (-15% YoY, -21% QoQ)
  • Finance costs: Q2 FY27 ₹12 million (64% YoY growth, 104% QoQ growth)
  • Tax: Q2 FY27 ₹176 million (19% YoY growth, 18% QoQ growth)

Geographical Revenue Split

Not Specified for current period. FY26 data shows: India 46%, Americas 37%, Europe 5%, Asia (ex-India) 9%, Rest of the World 3%

Balance Sheet Snapshot

FY26 Audited (Consolidated):

  • Property, plant and equipment: ₹2,758 million
  • Capital work-in-progress: ₹512 million
  • Intangible assets: ₹469 million
  • Goodwill: ₹3,695 million
  • Other non-current assets: ₹518 million
  • Current assets: ₹10,436 million
  • Total Assets: ₹18,388 million
  • Equity share capital: ₹224 million
  • Other equity: ₹16,096 million
  • Non-controlling interest: ₹512 million
  • Non-current liabilities: ₹489 million
  • Current liabilities: ₹1,067 million

Capex & Cash Flow Health

Not Specified

Strategic & R&D Initiatives

Future Growth Drivers:

  • Continued Investment in R&D to identify product gaps and develop new enzymes, probiotics & solutions
  • Expand competencies in enzymes & probiotics, discovery and genetic engineering
  • Broaden & deepen geographical presence with increased focus on high return applications
  • Build strategic partnerships in key markets for focus segments
  • Inorganic expansion through acquisition of key technologies, competencies & skill-sets

Focus Areas Going Ahead:

  • Animal Nutrition: Conduct trials for newer nutritional products, register more products domestically and internationally
  • Bio-Catalysis: Develop bio catalysis for API manufacturers, couple of products under advanced stage of trials
  • Probiotics: Introduce more products for human nutrition for immunity development and gut health
  • Baking: Expand baking solutions in Europe, Americas and Rest of World

Industry Trends & Business Environment

Not Specified

Management Commentary & Growth Outlook

Not Specified